Hubbry Logo
BromodomainBromodomainMain
Open search
Bromodomain
Community hub
Bromodomain
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Bromodomain
Bromodomain
Bromodomain
View on Wikipedia
from Wikipedia
Bromodomain
Ribbon diagram of the GCN5 bromodomain from Saccharomyces cerevisiae, colored from blue (N-terminus) to red (C-terminus).[1]
Identifiers
SymbolBromodomain
PfamPF00439
InterProIPR001487
SMARTSM00297
PROSITEPDOC00550
SCOP21b91 / SCOPe / SUPFAM
CDDcd04369
Available protein structures:
PDB  1e6i​, 1eqf​, 1f68​, 1jm4​, 1jsp​, 1n72​, 1wug​, 1wum​, 1zs5​, 2d82​ IPR001487 PF00439 (ECOD; PDBsum)  
AlphaFold

A bromodomain is an approximately 110 amino acid protein domain that recognizes acetylated lysine residues, such as those on the N-terminal tails of histones. Bromodomains, as the "readers" of lysine acetylation, are responsible in transducing the signal carried by acetylated lysine residues and translating it into various normal or abnormal phenotypes.[2] Their affinity is higher for regions where multiple acetylation sites exist in proximity. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. The domain itself adopts an all-α protein fold, a bundle of four alpha helices each separated by loop regions of variable lengths that form a hydrophobic pocket that recognizes the acetyl lysine.[1][3]

Discovery

[edit]

The bromodomain was identified as a novel structural motif by John W. Tamkun and colleagues studying the Drosophila gene Brahma/brm, and showed sequence similarity to genes involved in transcriptional activation.[4] The name "bromodomain" is derived from the relationship of this domain with Brahma and is unrelated to the chemical element bromine.

Bromodomain-containing proteins

[edit]

Bromodomain-containing proteins can have a wide variety of functions, ranging from histone acetyltransferase activity and chromatin remodeling to transcriptional mediation and co-activation. Of the 43 known in 2015, 11 had two bromodomains, and one protein had 6 bromodomains.[2] Preparation, biochemical analysis, and structure determination of the bromodomain containing proteins have been described in detail.[5]

Bromo- and Extra-Terminal domain (BET) family

[edit]

A well-known example of a bromodomain family is the BET (Bromodomain and extraterminal domain) family. Members of this family include BRD2, BRD3, BRD4 and BRDT.[6]

Other

[edit]

However proteins such as ASH1L also contain a bromodomain. Dysfunction of BRD proteins has been linked to diseases such as human squamous cell carcinoma and other forms of cancer.[7] Histone acetyltransferases, including EP300 and PCAF, have bromodomains in addition to acetyl-transferase domains.[8][9][10]

Not considered part of the BET family (yet containing a bromodomain) are BRD7, and BRD9.

Role in human disease

[edit]

The role of bromodomains in translating a deregulated cell acetylome into disease phenotypes was recently unveiled by the development of small molecule bromodomain inhibitors. This breakthrough discovery highlighted bromodomain-containing proteins as key players in cancer biology, as well as inflammation[11] and remyelination in multiple sclerosis.[2]

Members of the BET family have been implicated as targets in both human cancer[12][13] and multiple sclerosis.[14] BET inhibitors have shown therapeutic effects in multiple preclinical models of cancer and are currently in clinical trials in the United States.[15] Their application in multiple sclerosis is still in the preclinical stage.

Small molecule inhibitors of non-BET bromodomain proteins BRD7 and BRD9 have also been developed.[16][17]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Bromodomain

View on Grokipedia
from Grokipedia
A bromodomain is a conserved protein structural domain comprising approximately 110 that specifically recognizes and binds to acetylated residues, primarily on tails, thereby acting as an epigenetic "reader" in the regulation of structure and transcription. The bromodomain was first identified in 1992 as a motif present in proteins from humans, , and , initially noted in the Drosophila brahma involved in . Structurally, it forms a compact, left-handed bundle of four alpha-helices (designated αZ, αA, αB, and αC), connected by loops (ZA and BC) that create a deep, hydrophobic pocket for acetyl-lysine binding, with variations in loop lengths conferring specificity among different bromodomains. In the human proteome, there are 61 bromodomains distributed across 46 proteins, classified into eight subfamilies based on sequence similarity and phylogenetic analysis. Functionally, bromodomains mediate protein-protein interactions by recruiting chromatin-associated factors to acetylated sites, facilitating processes such as histone acetylation-dependent transcription activation, , repair, and recombination. The bromodomain and extra-terminal (BET) subfamily, including proteins like BRD2, BRD3, , and BRDT—each containing two tandem bromodomains—plays a particularly prominent role in by associating with acetylated s and recruiting co-activators like the positive transcription elongation factor b (P-TEFb). Dysregulation of bromodomain-containing proteins is implicated in various diseases, notably cancers where such as have shown therapeutic potential by disrupting oncogenic transcription programs.

Definition and Structure

Definition

The bromodomain is a conserved consisting of approximately 110 that specifically recognizes and binds to acetylated residues (AcK), particularly those on the N-terminal tails of . This binding module is one of the primary that specifically interact with acetyl-lysine modifications, enabling selective recruitment of proteins to sites marked by histone acetylation. As an "epigenetic reader," the bromodomain interprets post-translational modifications like lysine acetylation, translating these chemical signals into functional outcomes that regulate gene expression. It serves as a key interpreter in the epigenetic code, facilitating the dynamic control of chromatin states without altering the underlying DNA sequence. Bromodomains are found in a variety of eukaryotic proteins that participate in processes such as , transcriptional activation, and cellular signaling pathways. These domains are evolutionarily conserved across all eukaryotes, reflecting their fundamental role in gene regulation, with the containing 61 bromodomains distributed across 46 distinct proteins.

Structural Features

The bromodomain is characterized by a compact all-α helical comprising four conserved alpha helices, labeled αZ, αA, αB, and αC, arranged in a left-handed bundle. These helices are interconnected by flexible loops, notably the ZA loop linking αZ and αA, and the BC loop connecting αB and αC, which contribute to the domain's overall architecture and ligand accessibility. This , approximately 110 in length, is highly conserved across the 61 human bromodomains, enabling their role in recognizing post-translational modifications. A defining feature of the bromodomain is the deep hydrophobic pocket formed by the and BC loops at the interface of the four helices, which accommodates the acetylated (AcK) . Within this pocket, a conserved residue in the BC loop forms a with the oxygen of the , while conserved molecules in the pocket further stabilize the interaction through s involving the of AcK. A conserved residue in the loop contributes to pocket stability. These interactions, first detailed in the solution structure of the PCAF bromodomain, ensure specific binding to the hydrophobic of the acetyl moiety. Structural variations among bromodomains arise from differences in loop lengths, particularly in the and BC regions, and substitutions in pocket-lining residues, leading to diversity in binding pocket size and shape. For instance, some bromodomains exhibit narrower pockets with enhanced specificity for certain AcK contexts, while others have more spacious cavities that accommodate bulkier ligands, influencing overall affinity in the micromolar range. The first high-resolution of a bromodomain was solved in 1999 using NMR for the PCAF bromodomain, highlighting conserved elements like the loop and setting the foundation for subsequent crystallographic studies across the family.

History and Discovery

Initial Identification

The bromodomain motif was first identified in 1992 by Tamkun and colleagues during the sequencing and molecular analysis of the Drosophila melanogaster gene brahma (brm), which encodes a protein required for the activation of multiple homeotic genes and functions as a homolog of the factors. Shortly thereafter, Haynes and colleagues named this novel structural feature the "bromodomain" and described it as an approximately 110-amino-acid motif present in the Brm protein and evolutionarily conserved in related proteins from humans, , and , including the transcriptional activators SWI2/SNF2 and the human brahma-related gene 1 (BRG1). The discovery immediately established an initial connection between the bromodomain and transcriptional activation, as the Brm protein acts as a key regulator of in . Later investigations in the 2000s revealed associations of Brm-containing complexes with histone acetyltransferases (HATs), which promote accessibility for transcription. Early biochemical assays on Brm-containing complexes, purified from Drosophila embryo nuclear extracts, further characterized their functional properties, demonstrating DNA-stimulated activity dependent on the Brm subunit and capabilities that facilitate DNA accessibility, consistent with a role in .

Key Milestones in Research

Following the initial identification of the bromodomain motif in 1992 within the Brahma protein, research advanced significantly in the late 1990s with the determination of the first high-resolution structure of a bromodomain. In 1999, Dhalluin and colleagues solved the solution structure of the PCAF bromodomain bound to an acetyl- (AcK) , revealing a conserved hydrophobic binding pocket formed by four alpha-helices that specifically recognizes the acetylated lysine side chain on tails. This structural insight confirmed the bromodomain's role as a dedicated acetyl-lysine reader module, laying the foundation for understanding its function in epigenetic signaling. During the 2000s, studies expanded on this discovery by identifying and characterizing bromodomains in key histone acetyltransferases (HATs), such as p300 and CBP, and elucidating their contributions to acetyl-lysine recognition. The bromodomains in p300 and CBP were shown to bind acetylated substrates, facilitating recruitment of these HATs to and promoting further acetylation in a feed-forward mechanism that enhances transcriptional activation. These findings highlighted how bromodomains in HATs like p300/CBP integrate acetyl-lysine reading with writing activities, influencing in diverse cellular processes. A pivotal occurred in 2010 with the development of , the first selective small-molecule inhibitor targeting BET bromodomains, by the Bradner laboratory. competitively binds the acetyl-lysine pocket of BET proteins like , displacing them from and enabling precise chemical probe studies to dissect bromodomain functions in transcription regulation. This tool compound revolutionized the field by demonstrating the therapeutic potential of bromodomain inhibition and spurring widespread adoption of approaches in research. From 2015 to 2023, bromodomain research benefited from comprehensive genomic annotations and advanced functional screening technologies. Databases such as cataloged 61 distinct bromodomains across 46 human proteins, providing a complete inventory that facilitated systematic classification into eight structural families based on sequence and phylogenetic analyses. Concurrently, integration with CRISPR-Cas9 screens enabled large-scale studies, identifying essential roles of specific bromodomains in processes like and differentiation through genome-wide knockouts.

Biological Functions

Role in Epigenetic Regulation

Bromodomains serve as epigenetic readers that specifically recognize and bind to acetylated residues on tails, such as H3K14ac and H4K16ac, thereby recruiting bromodomain-containing proteins to sites marked by these modifications. This binding event facilitates the transition to an open conformation known as , which promotes accessibility of transcriptional machinery to DNA and enhances . By anchoring regulatory complexes at these acetylated loci, bromodomains contribute to the dynamic remodeling of structure during transcriptional activation. In coordination with histone acetyltransferases (HATs), bromodomains enable the propagation and interpretation of acetylation patterns as part of the histone code hypothesis, which posits that combinations of histone modifications form a "code" recognized by specific reader domains to orchestrate gene regulation. Many HATs, such as PCAF and CBP/p300, themselves contain bromodomains that bind nascent acetylated s, allowing these enzymes to be retained at for iterative acetylation and amplification of the mark. This reader-writer synergy integrates bromodomains into broader epigenetic networks involving other writers and readers, ensuring precise control over states and transcriptional outcomes. Bromodomains play a pivotal role in activating enhancers and promoters by coactivators to acetylated regions, thereby facilitating the assembly of transcription complexes. In particular, BET family proteins with tandem bromodomains concentrate at super-enhancers—large clusters of enhancers enriched in acetylated histones—to drive high-level expression of key regulatory genes. This mechanism amplifies transcriptional output at critical loci, underscoring bromodomains' function in establishing cell-type-specific programs. Dysregulation of bromodomain-mediated recognition can lead to aberrant deposition or persistence of epigenetic marks, disrupting normal gene regulation and contributing to pathological states.

Interactions with and Proteins

Bromodomains recognize acetylated residues on tails with moderate binding affinities, typically exhibiting dissociation constants (Kd) in the range of 1–30 μM for acetylated . For instance, the first bromodomain of binds to a di-acetylated H4K12ac/K16ac with a Kd of approximately 22 μM, as determined by . This binding is specific to the acetyl-lysine motif, with bromodomains showing a for di-acetylated over mono-acetylated histones; binding assays demonstrate that avidly interacts with di- and tetra-acetylated H4 (e.g., at Lys5 and Lys12) but only weakly with mono-acetylated forms. In proteins containing tandem bromodomains, such as , the dual modules enable cooperative engagement of multiple acetyl-lysine sites on the same , increasing overall for . Structural studies reveal that the first and second bromodomains of can simultaneously bind distinct acetyl-lysines, such as K8ac and K12ac on H4, facilitating stable association with multiply acetylated nucleosomes. This multivalent binding mode enhances the protein's retention on compared to single bromodomain interactions. Beyond direct engagement, bromodomains promote protein-protein interactions that assemble transcriptional complexes. For example, uses its bromodomains to recruit the Mediator coactivator complex to acetylated promoters, bridging chromatin readers with the core transcription machinery. Similarly, bromodomain-mediated binding of to acetylated histones facilitates the recruitment of P-TEFb (positive transcription elongation factor b), which phosphorylates the C-terminal domain to release promoter-proximal pausing and promote elongation. These interactions are highly dynamic, characterized by rapid exchange on . loss in (FLIP) assays indicate that bromodomain proteins like exhibit residence times ranging from seconds to minutes on acetylated , reflecting a "hit-and-run" mechanism that allows for transient but frequent rebinding. Increased chromatin , such as following inhibition, reduces mobility, prolonging its dwell time and stabilizing associations.

Bromodomain-Containing Proteins

BET Family Proteins

The BET family, or bromodomain and extraterminal () subfamily, consists of four proteins in humans: BRD2, BRD3, , and BRDT. Each member features two N-terminal bromodomains, designated BD1 and BD2, which recognize and bind acetylated residues on tails, along with a C-terminal extraterminal (ET) domain that facilitates protein-protein interactions and recruitment to . The tandem arrangement of BD1 and BD2 enables to di-acetylated histones, enhancing specificity and affinity for targets. BRD4 is the most extensively studied BET protein, known for its localization to mitotic chromosomes throughout , where it maintains epigenetic bookmarks for post-mitotic reactivation. It also associates with super-enhancers, clusters of enhancers that drive high-level expression of key by recruiting transcriptional machinery. In contrast, BRDT exhibits tissue-specific expression restricted to the testis, playing an essential role in through regulation of during . BET proteins collectively contribute to cell cycle progression by interacting with factors like E2F1 to regulate genes and origins. They also modulate inflammatory gene expression, particularly by enhancing pathway activity; for instance, and BRD2 bind acetylated (p65) to promote transcription of proinflammatory cytokines such as IL6 and CXCL8. The BD1 and BD2 pockets across proteins are highly conserved, sharing over 75% sequence identity, which allows broad recognition of acetylated motifs but with subtle differences in selectivity—for example, BRD4's BD2 shows preferential affinity for di-acetylated H4K5/K12. These variations influence isoform-specific functions while preserving the family's core role in linking histone acetylation to transcriptional outcomes.

Non-BET Bromodomain Proteins

Non-BET bromodomain proteins represent the predominant group among the 46 bromodomain-containing proteins encoded in the , comprising approximately 42 proteins that collectively harbor 53 of the 61 known bromodomains. These proteins display substantial structural and functional diversity, often integrating a single bromodomain with other motifs such as domains, domains, or activity, enabling specialized roles in dynamics beyond the tandem bromodomain architecture characteristic of the BET family. This heterogeneity underscores their involvement in a broad array of epigenetic processes, including transcription regulation, , and metabolic pathways, where they act as scaffolds in multi-protein complexes. Prominent examples of non-BET proteins with single bromodomains include the histone acetyltransferases PCAF (KAT2B) and p300 (EP300), which not only catalyze acetylation of s and non-histone substrates but also recruit transcriptional machinery via their bromodomains' recognition of acetyl-lysine marks. PCAF functions within the SAGA chromatin-modifying complex to promote gene activation, particularly in response to cellular signals, while p300 serves as a versatile co-activator that bridges transcription factors to the basal machinery, influencing pathways like and . These HATs exemplify how non-BET bromodomains integrate "writing" and "reading" of epigenetic marks to fine-tune . Other non-BET proteins incorporate bromodomains into larger multifunctional contexts, such as BRG1 (SMARCA4), which possesses one bromodomain and drives ATP-dependent nucleosome remodeling as the catalytic subunit of SWI/SNF complexes, thereby facilitating access to DNA for replication and transcription. Similarly, ATAD2, featuring a bromodomain alongside its AAA+ ATPase domain, supports DNA replication fork progression and cell cycle advancement, often in association with estrogen receptor signaling. Specialized functions are further illustrated by BAZ1B (WSTF), which aids nucleosome remodeling and assembly in the context of DNA damage response, and TRIM28 (KAP1), a scaffolding protein with a bromodomain that coordinates heterochromatin formation through ubiquitin-mediated recruitment of repressive factors. These examples highlight the non-BET proteins' adaptability in maintaining chromatin architecture and silencing mechanisms. Structurally, the bromodomains of non- proteins exhibit less conservation in their acetyl-lysine binding pockets relative to BET bromodomains, featuring variable residues like or aspartate that confer distinct affinities and specificities. This reduced conservation contributes to their diverse interactions with acetylated substrates and complicates the design of targeted inhibitors, emphasizing the need for protein-specific approaches in therapeutic development.

Involvement in Human Diseases

Role in Cancer

Bromodomains play a pivotal role in oncogenesis through their involvement in epigenetic regulation, particularly via the BET family proteins such as , which recognize acetylated lysine residues on to facilitate gene transcription. In NUT midline carcinoma, a rare and aggressive squamous cell cancer, the -NUT fusion protein aberrantly recruits the p300 to promoters, driving hyper and sustained expression of oncogenic genes, thereby initiating tumorigenesis.00410-9) Similarly, in (AML), binds to super-enhancers—clusters of enhancers marked by high levels of histone —to amplify the transcription of the , promoting leukemic and survival.00393-0) This MYC-driven mechanism underscores how BET bromodomains sustain core transcriptional programs essential for cancer maintenance. Overexpression of bromodomain-containing proteins, notably , is frequently observed in solid tumors and contributes to tumor progression by enhancing and inhibiting . In , elevated BRD4 levels correlate with increased malignancy, where it recruits transcriptional machinery to promoters of genes involved in epithelial-mesenchymal transition and progression, thereby fostering invasive growth. Likewise, in , BRD4 cooperates with nucleophosmin 1 to boost c-Myc expression, driving androgen-independent proliferation and . These examples illustrate how dysregulated bromodomain activity in solid tumors exploits acetyl-lysine marks to reprogram networks favoring oncogenesis. Beyond BET proteins, mutations in non-BET bromodomain-containing factors, such as BRG1 (encoded by ), disrupt and contribute to cancer development. Loss-of-function mutations in BRG1, common in non-small cell lung cancer and other malignancies, impair the complex's ability to reposition nucleosomes at acetylated sites, leading to defective gene activation or repression and genomic instability. This deficiency allows aberrant accumulation of oncogenic signals, highlighting bromodomains' broader role in maintaining epigenetic integrity. Aberrant recognition of acetyl-lysine (AcK) residues by bromodomains in cancer cells drives epigenetic reprogramming, enabling the sustained activation of pro-tumorigenic pathways. Hyperacetylation of histones in tumor microenvironments enhances bromodomain binding to enhancers and promoters, resulting in the misregulation of genes that promote survival and , as seen across various carcinomas. This dysregulated AcK-bromodomain interaction represents a hallmark of cancer , distinct from normal cellular processes.

Role in Non-Cancer Diseases

Bromodomains, particularly those in family proteins like , play significant roles in inflammatory diseases by regulating production through (LPS)-induced pathways. In (), mediates the expression of proinflammatory s such as IL-6, IL-1β, and TNF-α in macrophages stimulated by LPS, contributing to synovial and joint destruction. Silencing , along with BRD2 and BRD3, reduces these levels in bone marrow-derived macrophages, highlighting BET proteins' involvement in RA . Similarly, in (), drives airway and by promoting M1 macrophage polarization and release in response to LPS and exposure. Pharmacological inhibition of ameliorates experimental by disrupting super-enhancers in polarized alveolar macrophages, thereby attenuating obstructive airflow limitation and inflammatory cell infiltration. In neurological disorders such as (MS), regulates Th17 cell differentiation, exacerbating . is essential for the production of Th17-associated cytokines including IL-17 and IL-21, which promote autoimmune responses in experimental autoimmune encephalomyelitis (EAE), a model for MS. Inhibition of the BET N-terminal bromodomain selectively blocks Th17 lineage commitment by suppressing key transcriptional programs, thereby reducing disease severity in MS models. expression in CD4+ T cells and further supports T cell recruitment into the , amplifying Th17-driven pathology. Emerging evidence implicates bromodomains in cardiovascular diseases, with contributing to progression. In LPS-challenged macrophages, induces and enhances lipid uptake via scavenger receptors, fostering plaque formation in arterial walls. also regulates vascular cell proliferation and migration under hyperglycemic conditions, accelerating diabetic through pathways involving Pin1 signaling. These mechanisms underscore 's role in linking to atherogenic processes. Bromodomains influence viral persistence in infectious diseases, notably latency. BRD4 acts as a negative regulator of HIV-1 transcription by competing with the viral Tat protein for binding to acetylated histones at the proviral , maintaining latency in resting + T cells. Disruption of BRD4's bromodomain via inhibitors like reactivates latent HIV-1 proviruses by relieving this repression and facilitating Tat-dependent elongation, offering a strategy for clearance without excessive T cell activation. This approach upregulates histone-modifying genes that favor proviral expression. Beyond BET proteins, non-BET bromodomains such as that in BAZ2B are linked to neurodevelopmental disorders. of BAZ2B, often due to de novo heterozygous variants, causes developmental delay, , and autism spectrum disorder features by impairing and gene regulation during brain development. Loss-of-function mutations in BAZ2B disrupt its role as a subunit in ATP-dependent chromatin complexes like BRF1 and BRF5, leading to altered DNA-templated processes essential for neurodevelopment. These phenotypes are recurrently associated with BAZ2B deficiency, confirming its causal role in non-syndromic neurodevelopmental conditions.

Therapeutic Targeting

Bromodomain Inhibitors

Bromodomain inhibitors are small molecules that competitively bind to the acetyl-lysine (AcK) recognition pocket of bromodomains, thereby disrupting their interaction with acetylated histones and other proteins to modulate epigenetic signaling. These inhibitors typically mimic the acetyl-lysine motif and exhibit nanomolar potency, with many targeting the bromodomain and extra-terminal (BET) family proteins due to their conserved pocket architecture. Early developments focused on BET inhibitors (BETi), such as , introduced in 2010 as a that selectively occupies the AcK-binding site of with IC50 values of 77 nM for the first bromodomain (BD1) and 33 nM for the second (BD2). Similarly, I-BET762, another from GlaxoSmithKline, binds BET bromodomains with IC50 values ranging from 32.5 to 42.5 nM across BRD2, BRD3, and , effectively displacing BET proteins from . OTX015 (also known as MK-8628), a structurally related BETi, shows comparable affinity with IC50 values of 92–112 nM for BET bromodomains, inhibiting proliferation in hematologic malignancies by blocking transcription. Beyond BET proteins, inhibitors have been developed to exploit structural variations in non-BET bromodomains for greater selectivity. For instance, selective inhibitors of BRD7 and BRD9 bromodomains, components of SWI/SNF chromatin remodeling complexes, include triazolodiazepine derivatives like compound 8, which binds with pIC50 values of 7.5 for BRD7 and 7.8 for BRD9, leveraging a unique asparagine residue in their AcK pockets to differentiate from BET family members. GSK2801 serves as a chemical probe for BRD9 (and BAZ2A/B) with a Kd of approximately 20 nM for BRD9, demonstrating how subtle pocket differences enable targeted inhibition outside the BET subfamily. For the PCAF bromodomain, a histone acetyltransferase involved in gene activation, L-Moses (L-45) acts as a potent chemical probe with a Kd of 126 nM, selectively disrupting PCAF-histone interactions in cells via a nanoBRET assay while showing over 4500-fold selectivity against BRD4. To address proteins with multiple bromodomains, such as the tandem BD1 and BD2 in family members, dual or tandem inhibitors have been designed to simultaneously engage both domains, enhancing and . Examples include bivalent that link two pharmacophores to span the BD1-BD2 interface, achieving sub-nanomolar potency against by exploiting the ~110 Å separation between pockets. Complementing these, proteolysis-targeting chimeras (PROTACs) like dBET6 induce ubiquitin-mediated degradation of proteins rather than mere inhibition; dBET6, a JQ1-thalidomide conjugate, potently degrades (IC50 ~14 nM) by recruiting the E3 ligase , leading to sustained target suppression and antitumor effects in models of . This approach circumvents resistance from incomplete displacement but requires cellular permeability for the larger bifunctional molecule. Achieving selectivity remains a key challenge for bromodomain inhibitors, as the conserved AcK-binding ZA loop and WPF shelf motifs across the 61 human bromodomains often lead to off-target binding and toxicity. Structural studies reveal that variations in the asparagine gatekeeper residue (e.g., Asn116 in BRD4 vs. Asp in non-BET) guide probe design, yet pan-inhibitors like early BETi can cross-react with distant family members, complicating therapeutic windows. Off-target effects, such as unintended degradation by PROTACs or kinase inhibition by dual-target compounds, underscore the need for high-resolution co-crystal structures to refine specificity, as seen in BRD7/BRD9 inhibitors that avoid BET cross-talk through pocket-specific substituents.

Clinical and Therapeutic Developments

As of November 2025, several bromodomain and extra-terminal ( have advanced to phase II and III clinical trials, primarily targeting hematologic malignancies and solid tumors. Pelabresib (CPI-0610), a selective , combined with in the phase II MANIFEST trial (NCT02158858) for JAK inhibitor-naïve myelofibrosis patients, demonstrated substantial and durable reductions in and symptom burden. The phase III MANIFEST-2 study (NCT04603495) met its primary endpoint, with 66% of patients on pelabresib plus achieving a ≥35% spleen volume reduction at week 24 compared to 35% on plus . ZEN-3694, a pan-, is under investigation in phase II trials such as NCT05327010, where it is combined with for solid tumors harboring deficiencies, showing preliminary antitumor activity. In 2025, ZEN-3694 received FDA designation for and fast track designation in combination with for unresectable or metastatic . It is also being investigated in a phase IIb randomized study (NCT04986423) of ZEN-3694 plus versus alone in metastatic castration-resistant . Molibresib (GSK525762), an oral , has shown single-agent activity in phase I/II studies for midline carcinoma and advanced solid tumors, including a 50% response rate in cutaneous T-cell lymphoma subtypes, though development has focused on combination regimens like with for hormone receptor-positive . Combination therapies involving are emerging to overcome monotherapy limitations and enhance efficacy in immuno-oncology. Preclinical data indicate that , such as PLX51107, can synergize with PD-1/ checkpoint inhibitors to boost T-cell infiltration and response in by reducing PD-1 expression on + T cells. In (AML), sequential or concurrent BET inhibition with JAK inhibitors like has shown promise in phase II settings for improving remission rates. Approximately 50 clinical trials worldwide have evaluated across various cancers, with combinations addressing resistance and expanding applications beyond to autoimmune diseases, as seen in the phase I/II IND approval for JAB-8263 in inflammatory conditions. Despite these advances, clinical translation faces significant challenges, including resistance mechanisms and toxicity profiles. Resistance to often arises from BRD4 stabilization via SPOP mutations in or compensatory redistribution of epigenetic regulators like p300 to maintain oncogenic in AML. emerges as the most common dose-limiting toxicity across BET inhibitors, linked to exposure-dependent suppression of maturation and platelet production, affecting up to 80% of patients in early trials and necessitating dose adjustments or supportive care. Biomarkers such as NFE2 and PF4 have been identified to predict and monitor this hematologic adverse event, guiding safer therapeutic windows. Emerging non-BET bromodomain therapies, particularly -targeted degraders, are in preclinical stages for inflammatory diseases. PROTAC-based degraders like XZ1606 have demonstrated reversal of hepatic and in mouse models by selectively eliminating protein, offering potential advantages over inhibitors by avoiding partial occupancy and reducing off-target effects. These degraders also show efficacy in ameliorating airway inflammation and in preclinical assays, highlighting 's role in pro-inflammatory gene networks without the seen in pan-BET inhibitors.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC6984398/
  2. https://academic.oup.com/nar/article/20/10/2603/1071823
  3. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/bromodomain
  4. https://www.nature.com/articles/s41392-023-01647-6
  5. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.818891/full
  6. https://www.embopress.org/doi/10.1093/emboj/19.22.6141
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC2921942/
  8. https://pubmed.ncbi.nlm.nih.gov/11911891/
  9. https://www.sciencedirect.com/topics/neuroscience/bromodomain
  10. https://www.frontiersin.org/journals/bioinformatics/articles/10.3389/fbinf.2022.835892/full
  11. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2012.04.045
  12. https://www.sciencedirect.com/science/article/abs/pii/S007668791600063X
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC7295032/
  14. https://link.springer.com/article/10.1186/s43556-023-00127-1
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12361904/
  16. https://doi.org/10.1016/j.cell.2012.02.013
  17. https://pubmed.ncbi.nlm.nih.gov/1346755/
  18. https://pubmed.ncbi.nlm.nih.gov/1350857/
  19. https://pubmed.ncbi.nlm.nih.gov/11257117/
  20. https://pubmed.ncbi.nlm.nih.gov/9735357/
  21. https://pubmed.ncbi.nlm.nih.gov/10365964/
  22. https://pubmed.ncbi.nlm.nih.gov/15004557/
  23. https://pubmed.ncbi.nlm.nih.gov/20831800/
  24. https://pubmed.ncbi.nlm.nih.gov/28209918/
  25. https://www.nature.com/articles/s41467-019-12489-8
  26. https://www.sciencedirect.com/science/article/pii/S1097276503004829
  27. https://www.mdpi.com/2073-4425/3/2/320
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3899951/
  29. https://www.cell.com/cell/fulltext/S0092-8674(01)00563-6
  30. https://www.nature.com/articles/s41467-023-39735-4
  31. https://www.pnas.org/doi/10.1073/pnas.1433065100
  32. https://www.cell.com/cell/fulltext/S0092-8674(13)00633-9
  33. https://www.nature.com/articles/s41420-023-01775-6
  34. https://pubs.acs.org/doi/10.1021/acs.biochem.2c00226
  35. https://www.sciencedirect.com/science/article/pii/S1097276505014310
  36. https://www.nature.com/articles/s41392-020-00384-4
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC7029111/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4018722/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC3454531/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC5644722/
  41. https://www.nature.com/articles/s41418-019-0353-2
  42. https://www.nature.com/articles/s41420-023-01682-w
  43. https://www.nature.com/articles/ncomms14098
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC6269638/
  45. https://academic.oup.com/rheumatology/article/55/1/173/1794957
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC11786429/
  47. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0095051
  48. https://www.sciencedirect.com/science/article/abs/pii/S1567576924011676
  49. https://www.pnas.org/doi/10.1073/pnas.1615601114
  50. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-025-03449-9
  51. https://www.aging-us.com/article/103200/text
  52. https://pubmed.ncbi.nlm.nih.gov/32409773/
  53. https://onlinelibrary.wiley.com/doi/10.1155/2020/4196482
  54. https://www.sciencedirect.com/science/article/pii/S2211124712002896
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC3501896/
  56. https://academic.oup.com/nar/article/41/1/277/1184625
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC7262739/
  58. https://pubmed.ncbi.nlm.nih.gov/37872713/
  59. https://pubmed.ncbi.nlm.nih.gov/31999386/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3010259/
  61. https://pubs.acs.org/doi/10.1021/jm4014407
  62. https://aacrjournals.org/clincancerres/article/21/7/1628/248472/The-BET-Bromodomain-Inhibitor-OTX015-Affects
  63. https://pubs.rsc.org/en/content/articlelanding/2015/md/c5md00152h
  64. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00209
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC5412877/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC8837683/
  67. https://www.rndsystems.com/products/dbet6_6945
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC10314895/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC5321501/
  70. https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01980
  71. https://library.ehaweb.org/eha/2025/eha2025-congress/4159300/alessandro.vannucchi.pelabresib.in.combination.with.ruxolitinib.for.janus.html
  72. https://www.cancernetwork.com/view/zen-3694-earns-fda-orphan-drug-designation-in-nut-carcinoma
  73. https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5123
  74. https://www.esmoopen.com/article/S2059-7029%2825%2900368-0/fulltext
  75. https://aacrjournals.org/clincancerres/article/30/2/334/733189/A-Phase-I-II-Study-of-GSK525762-Combined-with
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC6591077/
  77. https://ashpublications.org/blood/article/145/7/660/535442/Sequential-epigenetic-therapy-in-AML
  78. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1592693/full
  79. https://www.prnewswire.com/news-releases/jacobios-ind-for-phase-i-ii-clinical-trial-of-bet-inhibitor-jab-8263-in-autoimmune-diseases-has-been-accepted-302497083.html
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC5788415/
  81. https://ashpublications.org/blood/article/145/7/748/534395/Acute-resistance-to-BET-inhibitors-remodels
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC7870522/
  83. https://www.thno.org/v15p7270.htm
  84. https://www.sciencedirect.com/science/article/pii/S016561472500224X
  85. https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-024-00641-6
Add your contribution
Related Hubs
User Avatar
No comments yet.